18 окт. 2023 г. · PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis ...

PURPOSE 5 is the latest example of Gilead's ongoing commitment and work to assess the potential of lenacapavir to help a diverse range of people around the ...

The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ... Purpose 1 · Purpose 2 · Purpose 3 · Purpose 4

The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting ...

PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV PrEP in France and the United Kingdom.

22 июн. 2024 г. · PURPOSE 5, enrolling people at high risk of HIV in France and the UK, was added in later when European regulators said they needed European ...

12 сент. 2024 г. · The Phase 2 and 3 program, consisting of PURPOSE 1-5, is assessing the potential of lenacapavir to help a diverse range of people around the ...

Purpose: The purpose of this study is to evaluate the pharmacokinetics of twice-yearly subcutaneous lenacapavir and to assess the safety of twice-yearly ...

Three smaller Phase II clinical trials PURPOSE 3, PURPOSE 4, and PURPOSE 5 are investigating safety and efficacy in populations not included in PURPOSE 1 and 2.

Lenacapavir is a long-acting, potent inhibitor of the HIV capsid protein with in vitro activity against viral strains resistant to other ARV classes. By ...